8th Annual Traumatic Brain Injury Conference Issues Call for Poster Session Submissions

Share Article

Abstracts will be Considered through April 27 for Opportunity to Present and Discuss Findings with Leaders Across TBI Research and Industry

Each submission must include full name and affiliation, poster title and abstract. Abstracts should be no more than 1,000 words and follow a standard format, featuring background, methods, results and conclusion. Submissions can be emailed to poster@tbiconference.com by April 27, and they will be reviewed and approved on a rolling basis. Notification of acceptance can be expected 3-5 business days after submission. Regular conference registration rates apply for all poster session presenters.

Traumatic Brain Injury Conference Issues Call for Poster Session Submissions. Abstracts will be Considered through April 27 to Present and Discuss Findings with Leaders Across TBI Research & Industry

The TBI Conference was designed as a forum for collaboration and industry advancement. The poster session follows that model, offering researchers a unique opportunity to discuss their work directly with the brightest minds in TBI research and development.

Arrowhead Publishers, host of the 8th annual Traumatic Brain Injury Conference, is accepting poster session abstract submissions through April 27. Successful candidates will have the opportunity to present recent findings in the area of TBI diagnostics and treatment at a Poster Session at the Traumatic Brain Injury Conference. The informal setting allows researchers to discuss their work with conference attendees, sponsors and speakers in an intimate atmosphere.

Each submission must include full name and affiliation, poster title and abstract. Abstracts should be no more than 1,000 words and follow a standard format, featuring background, methods, results and conclusion. Submissions can be emailed to poster@tbiconference.com by April 27, and they will be reviewed and approved on a rolling basis. Notification of acceptance can be expected 3-5 business days after submission. Regular conference registration rates apply for all poster session presenters.

The TBI Conference brings together physicians, nurses, neurosurgeons, scientists, and drug-diagnostic developers from all over the world to share insights and best practices. The event will return to Washington, D.C., May 16-17 at the Westin Arlington Gateway. It provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made toward better diagnosis, treatment and long-term care for TBI survivors. The conference has become a forum for leaders and high-level executives from the pharmaceutical, biotech, academic and government communities to discuss new avenues of research in the field of traumatic brain injury, and the latest advances in the field.

“We’re proud to continue our tradition of supporting emerging research through poster session presentations,” said John Waslif, Managing Director of Arrowhead Publishers. “The TBI Conference was designed as a forum for collaboration and industry advancement. The poster session follows that model, offering researchers a unique opportunity to discuss their work directly with the brightest minds in TBI research and development.”

Traumatic Brain Injury (TBI) is a major cause of death and disability globally, and is considered a serious health problem. In the United States, an estimated 1.7 million people sustain a traumatic brain injury each year, and more than 30 percent of all reported injury-related deaths list TBI as a contributing factor. Mild traumatic brain injury is the most common combat-related injury, and -- along with spinal cord injury -- TBI accounts for nearly 25 percent of combat casualties.

Treatment of TBI, and especially acute TBI, is still a major unmet medical need. Therapies that prove an ability to limit the damage done to the brain and improve clinical outcomes of patients of TBI will have a major impact on the global pharmaceutical market. Although past clinical trials for new therapies have ended in failure, emerging science has renewed interest across the medical and pharmaceutical fields. Recent initiatives from both the U.S. Congress and Department of Defense to improve treatment options for TBI patients are encouraging indications that the time has come for a rethinking of the potential for pharmaceutical management of conditions caused by traumatic brain injury.

There are several ways to participate in the conference and engage TBI experts and leaders:
Submit a Poster: http://www.tbiconference.com/home/poster-session
View the Agenda: http://www.tbiconference.com/home/2018agenda
Request a Brochure: http://www.tbiconference.com/home/brochure
Register to Attend: http://www.tbiconference.com
Explore Sponsorship and Exhibit Opportunities: http://www.tbiconference.com/home/sponsor-exhibit
Join the Mailing List: http://www.tbiconference.com/home/mailing-list
Keep up-to-date on conference news by following @tbiconference on Twitter and joining The Traumatic Brain Injury R&D Network on LinkedIn.
                                                                                                     # # #

Arrowhead Publishers brings life sciences industry professionals together to help move research forward through learning, networking and professional growth. Arrowhead focuses on offering thoughtfully curated speakers, new research industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Arrowhead conferences cover clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Waslif
Arrowhead Publishers
866-945-0263 (x 700)
Email >
Visit website